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Abstract
In this article, we discuss the most common epidemiological methods used for evaluating the ability of
mammography screening to decrease the risk of breast cancer death in general populations (effectiveness).
Case-control studies usually find substantial effectiveness. However when breast cancer mortality decreases for
reasons unrelated to screening, the case-control design may attribute to screening mortality reductions due to
other causes. Studies based on incidence-based mortality have obtained contrasted results compatible with
modest to considerable effectiveness, probably because of differences in study design and statistical analysis. In
areas where screening has been widespread for a long time, the incidence of advanced breast cancer should be
decreasing, which in turn would translate into reduced mortality. However, no or modest declines in the incidence
of advanced breast cancer has been observed in these areas. Breast cancer mortality should decrease more rapidly
in areas with early introduction of screening than in areas with late introduction of screening. Nonetheless, no
difference in breast mortality trends has been observed between areas with early or late screening start. When
effectiveness is assessed using incidence-based mortality studies, or the monitoring of advanced cancer incidence,
or trends in mortality, the ecological bias is an inherent limitation that is not easy to control. Minimization of this
bias requires data over long periods of time, careful selection of populations being compared and availability of
data on major confounding factors. If case-control studies seem apparently more adequate for evaluating
screening effectiveness, this design has its own limitations and results must be viewed with caution.
See related Opinion article: http://www.biomedcentral.com/1741-7015/10/106 and Commentary http://www.
biomedcentral.com/1741-7015/10/164
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Background
Four randomized trials conducted in Sweden from 1977
to 1993 obtained results suggesting 20% to 30% reduc-
tions in breast cancer mortality associated with the reg-
ular participation of women 40 to 74 years of age in
mammography screening [1-4]. These trials encouraged
the implementation of mammography screening services
and, in 2012, screening programs have been in place for
20 years or more in several high income countries.
Breast screening mobilizes considerable resources and
can generate harm due to false positive examinations,
overdiagnosis and overtreatment, the amount of which
depends on factors such as screening intensity, screening
ages, radiologist experience and the legal environment
(for example, defensive medicine in the US) [5-9]. An
essential question is thus the effectiveness of screening
activities, that is, are mortality reductions observed in the
ideal conditions of randomized trials (efficacy) also found
in the real world conditions of general population mass
screening (effectiveness)?
In their paper, Puliti and Zappa [10] posit that case-
control studies and studies based on incidence-based
mortality (IBM) constitute valid, unbiased evaluations of
screening effectiveness. By contrast, studies based on
mortality statistics have limitations that explain why
their findings are different from those of case-control
and IBM studies. As a result of these considerations, the
paper proposes to institute the case-control design as
the standard method for evaluating breast screening
effectiveness.
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In this opinion article, we briefly review the main
methods that have been used for evaluating the effec-
tiveness of breast screening and discuss their strengths
and weaknesses. Contrary to the opinion of Puliti and
Zappa, we suggest that the case-control study design
should not be used as the principal method to evaluate
the effectiveness of screening programs.
The case-control design
The case-control design compares the exposure to screen-
ing of women who died from breast cancer (the cases) to
that of women alive and still at risk of dying from breast
cancer at the time of death of the case (the controls). This
comparison is deemed to inform on the ability of regular
participation in screening to reduce the risk of dying from
breast cancer. This design is appealing because of its low
cost and swift execution [11].
The limitations of case-control designs for the evalua-
tion of screening effectiveness have been described [12].
However, case-control studies done after 2000 were per-
formed in populations where organized screening pro-
grams are established. These programs run databases
collecting all of the screening information of women living
in a country, including dates of invitation, participation,
screening result and follow-up that can be matched with
population-based cancer and cause of death registries.
Selecting and matching cases and controls from such data-
bases were deemed to guarantee equal opportunity of
exposure to screening of both cases and of controls and to
allow clear distinction between screening and diagnostic
mammography [13].
Despite these improvements, a major problem that
arises if the case-control study is conducted within the
context of a population screening program is that women
who do not participate in screening generally have a
poorer outcome [14-17] for reasons that are not related to
screening, thus inducing an observed lesser exposure to
screening among the cases [18]. A growing number of
data documents that, compared with women participating
in screening mammography, non-participating women
have characteristics associated with a higher risk of dying
from breast cancer, such as higher rates of obesity and
lower compliance to treatments, and the influence of these
characteristics on the risk of breast cancer death exists in
the absence of screening [19-21]. So, although a number
of non-participants die from breast cancer for reasons
unrelated to screening, results of case-control studies may
suggest that these deaths are due to not having been
screened. This bias in results has been termed the ‘self-
selection bias’. As the International Agency for Research
on Cancer (IARC) Handbook on Breast Cancer Screening
concluded, ‘Observational studies of screening, such as
cohort and case-control studies, may give biased measures
of effect because of self-selection of women for screening.
There are no certain ways of eliminating the bias’ [22].
In 2002, Duffy et al. proposed a method to correct
self-selection [18]. This method is based on computation
of a quantity ‘Dr’ that is the ratio of the breast cancer
mortality rate in non-participating women at the end of
a screening period to the rate in women not invited to
screening; that is, the rate in the control group of ran-
domized trials on breast screening or the rate in an area
before screening introduction. The quantity Dr is likely
to vary among populations where screening efficiency is
evaluated, because proportions of non-participants are
variable. Dr is expected to be closer to zero when parti-
cipation is low, because non-participants would be less
atypical of the general population [18].
Table 1 summarizes the effects of correcting for self-
selection in a population where breast screening is intro-
duced. As said before, women not likely to participate in
screening have a higher risk of breast cancer death that is
independent of the existence of screening. Thus, before
screening starts, the risk of breast cancer death of women
likely to participate in screening is known to be 30% to
60% lower than that of women unlikely to participate
[16-18]. For our example, we opted for a relative risk of
breast cancer death of 0.60, meaning that before screen-
ing starts, the risk of death in participants was 40% lower
than that in non-participants. The scenario in Panel A
assumes no effect of screening on breast cancer mortal-
ity. A case-control study after a period of screening will
find a crude risk of death of 0.61 in participants versus
non-participants, but the correction for self-selection will
yield an adjusted relative risk of 1.00, in agreement with
no screening effectiveness. In Panel B, a 20% mortality
reduction is obtained thanks to screening, and the cor-
rection leads to the right estimation of screening effec-
tiveness. Panels C and D are similar to Panels A and B,
but during the screening period, a 25% reduction change
in mortality occurs that is unrelated to screening (for
example, because of improved treatment). The Dr quan-
tities are smaller because improved treatments have
reduced the risk of breast cancer death in non-partici-
pants. As a consequence, the corrected relative risk in
Panel C suggests that participation in screening is asso-
ciated with a 44% (that is, 100 × (1.00-0.66)) reduction in
breast cancer mortality, when in reality screening had no
impact. The relative risk in Panel D is compatible with
true screening effectiveness but the estimated mortality
reduction of 52% (that is, 100 × (1.00-0.48)) is much lar-
ger than the 20% reduction actually due to screening.
In areas where all women are regularly invited for
screening, if breast cancer mortality changes for reasons
other than screening, observational studies can hardly
avoid the type of bias illustrated in Table 1. One could
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Table 1 Relative risk of breast cancer death before screening start in women likely and not likely to participate in screening, and relative risk of breast
cancer death after a period of screening with 75% participation.
Before
screening
After years of screening Correction according to Duffy et al. (2002) [18]
BC death
ratea
Change in mortality due
to screening












Participants 86 0% 0% 86
Non-participants 142 0% 0% 142
All womenb 100 0% 0% 100
RR breast cancer death, participants
versus non-participants
0.61 0.61 1.42 0.65 0.65 1.00
Panel
B
Participants 86 -20% 0% 69
Non-participants 142 0% 0% 142
All womenb 100 -15% 0% 85
RR breast cancer death, participants
versus non-participants
0.61 0.48 1.42 0.52 0.65 0.80
Panel
C
Participants 86 0% -25% 65
Non-participants 142 0% -25% 107
All womenb 100 0% -25% 75
RR breast cancer death, participants
versus non-participants
0.61 0.61 1.07 0.48 0.73 0.66
Panel
D
Participants 86 -20% -25% 47
Non-participants 142 0% -25% 107
All womenb 100 -15% -25% 60
RR breast cancer death, participants
versus non-participants
0.61 0.44 1.07 0.35 0.73 0.48
BC: Breast cancer; Dr: rate in non-participants after screening divided by the rate in all women before screening; p: participation rate of 75%; RR: relative risk. aPer 100,000 women-year. b(rate in participants × 0.75) +




















rely on breast cancer mortality rates in women of not
(yet) invited women. However, breast cancer survival var-
ies from region to region [23], and therefore, it is uncer-
tain whether rates observed in uninvited women are valid
for computing the quantity Dr. To be reliable, the quan-
tity Dr needs to be assessed for each study, and should
take into account changes in mortality due to factors
other than screening in both unscreened and in uninvited
women.
Incidence-based mortality studies
Incidence based mortality (IBM) studies compare breast
cancer mortality in patients with breast cancer diagnosed
during similar periods before (pre-screening period) and
after (screening period) screening introduction. Both
breast cancer diagnosis and death must occur during the
pre-screening or during the screening period. The advan-
tage of this method is that it uses the ‘refined mortality’
that is obtained by excluding breast cancer deaths due to
cancers diagnosed before start of the pre-screening per-
iod or before start of the screening period. IBM studies
are challenging as they require first the possibility to link
cancer registries to cause of death registries and second,
to assemble the exact data on women who had breast
cancer and died from it during the pre-screening and
during the screening period.
According to the IARC Handbook on Breast Cancer
Screening [22], ‘Refined mortality should be estimated
for screened and unscreened population to ensure com-
parability. Furthermore, cancer registration with data on
treatment is likely to be the only means for differentiating
the confounding effect of changes in treatment from the
effect of screening.’ Data on treatment is essential
because variations in breast cancer mortality changes
between regions may be due to differences in patient
management rather than to screening, and a number of
studies have documented substantial variability in patient
management across regions, including in Sweden [23-26].
IBM studies on breast cancer screening [27-34] are sum-
marized in Table 2. No study had data on patient manage-
ment in pre-screening and in screening periods and thus
no study could control for variations in patient manage-
ment between areas. In all IBM studies, individual expo-
sure to screening was generally known only for women
diagnosed with breast cancer, but not for other women.
Therefore, denominators (that is, person-years of exposure
or non-exposure to screening) were estimated at popula-
tion level, and not at individual level. In this respect, IBM
studies needs to be considered as ecological studies.
An IBM study in Finland based on data from the Fin-
ish Cancer Registry found an 11% mortality reduction
[31]. All four Swedish IBM studies obtained results indi-
cating considerable screening effectiveness [27,29,30,32].
However, in Sweden, breast cancer mortality has steadily
decreased by 0.9% per year since 1972, well before
screening started [35,36]. Because they had no compari-
son areas where no screening existed during the entire
study period, two IBM studies done in Sweden [27,29]
could not realize how these secular trends influenced
their results.
Swedish IBM studies corrected their results in various
ways (Table 2). Two studies corrected changes in breast
cancer mortality for changes in breast cancer incidence
[27,29]. This correction is based on the assumption that if
screening had not existed, trends in breast cancer mortal-
ity would have paralleled incidence trends. This correction
is not justified because first, in the absence of screening,
mortality and incidence trends are not correlated. Second,
mammography screening itself is the main cause of
increasing breast cancer incidence. The correction for lead
time is also questionable, as lead time is known to affect
survival statistics but not mortality [37].
Three IBM studies, one in Denmark [28] and two in
Norway [33,34], included comparison areas as well as his-
torical areas (that is, the screening and comparison areas
before screening start) where women were not invited to
screening (Table 2). The two studies in Norway were
based on the same screening areas but used different
comparison areas. The study in Denmark found a statisti-
cally significant 25% mortality reduction associated with
screening, while the two studies in Norway found 10%
and 7% reductions that were not statistically significant.
Despite comparable design, IBM studies in Denmark and
in Norway differed in several ways (Tables 2 and 3). In
Denmark, screening was mainly performed in Copenhagen,
the capital city. The data source for breast cancer cases was
the Copenhagen mammography screening register,
whereas for the rest of the country, a comparison group
was constructed from the central population register that
was linked to the Danish Cancer Registry. In Norway,
screening was initiated in four counties; in both studies,
the data source for breast cancer cases was the Norwegian
Cancer Registry. In Denmark, in the pre-screening period,
the mortality rate of Copenhagen women was 33% higher
(that is, 69 compared with 52) than among women living
elsewhere in Denmark (Table 3). Also, in comparison
areas, from the pre-screening to the screening period, no
decline in mortality rates occurred. Such contrast between
the screened and comparison areas did not exist in the
Norwegian studies. It is probable that the results of the
Danish study were owing to differences in ways by which
breast cancer cases were assembled in screened and in
comparison areas.
A final point is that IBM studies could underestimate
mortality reductions if substantial mammography screen-
ing is already present in comparison areas. Detailed infor-
mation on the provision of mammography examinations
in Sweden and Norway indicated that mammography
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screening outside the national breast screening programs
was uncommon [38-40].
Change in the incidence of advanced breast cancer
Clinical data show a strong correlation between the size
of breast cancer and the likelihood of metastases in axil-
lary lymph nodes or in distant organs. Breast cancer
screening is based on the principle that detection of a
cancer when still small and not symptomatic prevents
progression to advanced disease associated with positive
lymph nodes or distant metastases. The consequence of
early detection would be a reduction of the risk of death
from breast cancer.
Monitoring the incidence of advanced cancer thus
corresponds to the way screening works. In addition,
the incidence of advanced breast cancer is not influ-
enced by subsequent treatments. Therefore, in popula-
tions where breast screening has been widespread for a
long period of time (say, seven years or more), a reduc-
tion of advanced cancer incidence should reflect the
impact of screening activities alone. Longstanding broad
consensus exists for considering a decrease in advanced
breast cancer incidence as the best early indicator of the
impact of screening [1,22,41-43]. This consensus was in
agreement with cancer registry data showing marked
decreases in the incidence of advanced cervical and col-
orectal cancers over the last decades [44,45], which illu-
strated the contribution of screening to the reductions
in mortality from these two cancers. Of note, decreases
in the incidence of advanced breast cancer after screen-
ing introduction should not be confused with decreases
in proportions of advanced breast cancer [22]. The latter
does not necessarily reflect the influence of screening
because screening will increase numbers of early cancers
detected, due to lead time (advance in diagnosis) and to
length time (overdiagnosis). Increases in the number of
Table 2 Summary of main incidence-based mortality studies on breast cancer screening.











































50 to 69 No Yes Yes -25% No No No
SOSSEG
2006 [29]








































50 to 69 No Yes Yes -7 (NS) No No No
BC: breast cancer; NS: statistically non-significant. aData on breast cancer death rates in historical comparison groups, that is, in screening areas and in
comparison areas before screening started in screening areas.
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early cancer arithmetically lead to increases in propor-
tions of early cancer that in turn lead to decreases in
proportions of advanced cancer. Therefore, published
data show that proportions of advanced cancer usually
diminishes in years following breast screening introduc-
tion while concomitant reductions in the incidence rate
of advanced cancer may be modest or absent.
The IARC meeting of 2002 devoted a section on
trends in advanced breast cancer incidence [22]. How-
ever, at that time, few cancer registries had collected
adequate data over a too short period after screening
introduction.
From 2006 onwards, with accumulating years of screen-
ing activities in populations where good quality cancer
registries exist, larger amounts of data on advanced breast
cancer incidence were available. A systematic review
showed that, in areas in Europe, North America and
Australia where screening has been widespread for a long
time, no or small decreases in the incidence of advanced
and very advanced breast cancer was observed [46]. An
analysis of breast cancer incidence in the US reached the
same conclusion [47]. A team of radiologists performed an
in-depth analysis of screen-detected, interval and all breast
cancers diagnosed from 1989 to 2007 in the south-east
region of the Netherlands and found no decline in the
incidence of advanced breast cancer [48]. In the UK, can-
cer registry data for Scotland, Northern Ireland and the
West Midlands showed no decline in the incidence of
advanced breast cancer after the introduction of screening
in 1989 [46,49]. In Norway, the study that found a modest
non-significant reduction in the risk of breast cancer death
in screened versus non-screened populations [33] also
found no difference in rates of advanced breast cancer in
these populations [39].
A question is whether the incidence of advanced breast
cancer would have increased in the absence of screening.
Few data indicate that in areas where screening has been
widespread for some time, the answer is likely to be nega-
tive. In the Netherlands, where screening before 50 and
above 69 years of age was rare, there were no time changes
in the incidence of advanced breast cancer in women
younger than 50 and older than 69 years of age [42,50]. In
Victoria (Australia), the trends in the incidence of
advanced breast cancer in non-attending women were
similar to that observed among screened women [51].
Changes in breast cancer mortality rates in areas with
large difference in the timing of screening introduction
If breast screening was capable of reducing breast can-
cer mortality by 20% to 30% after seven to ten years,
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39 33 0.85 reference
Figures in the table are breast cancer mortality rates per 100,000 women ages 50 to 79 in Denmark and 50 to 84 in Norway. aRate ratios may slightly differ from
those of the original publications reported in Table 2 due to rounding and absence of statistical modelling. BC: breast cancer; NR: not reported.
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reductions should be quicker and more apparent in
countries with early screening implementation whereas
delayed and smaller reductions should be observed in
countries with late implementation.
The ecological design may be useful for comparative
effectiveness research, that is, comparison of disease-
specific trends in countries with similar quality of health
systems and access to treatment, but with different
prevention policies. This design has been used when ran-
domized trials were unfeasible, for example the banning
of smoking in public places in 2006 in Scotland was
followed by a one-year 17% reduction in hospital admis-
sions for acute myocardial events [52]. By contrast, in
England where such a ban did not yet exist, the hospital
admission during that one-year period decreased by 4%
[52]. In this respect, the IARC Handbook on Breast Can-
cer Screening stated that, ‘Routine screening programmes
can be evaluated most readily by time trends and differ-
ential mortality from the disease for which screening is
being performed. Probably the best known is screening
for cervical cancer. The substantial differences among
the Nordic countries in the extent of organized screening
were closely matched by the mortality rates from cervical
cancer (Läärä et al., 1987)’ [22].
Another study mimicked the Nordic study on cervical
cancer screening [53] by selecting three pairs of European
countries (the Netherlands and Belgium; Northern Ireland
and Ireland; Sweden and Norway) with similar prevalence
of risk factors for breast cancer death, access to treatment
and expenditures for health, but where by year 1993,
nationwide screening was in place in the first country of
each pair, but implemented 10 to 12 years later in the sec-
ond country [54]. In each country pair, breast cancer mor-
tality rates in 1987 to 1989 were comparable and from
1989 to 2007, equivalent declines in breast cancer mortal-
ity occurred. These results agreed with the observation
that breast cancer mortality reductions in high income
countries are unrelated to the temporal introduction of
screening mammography [35,55].
Perhaps a longer period would be needed to observe the
benefits of screening. However, in the Netherlands and the
UK, changes in mortality observed six to ten years after
screening introduction were attributed to screening
[56,57]. In this respect, the 18-year-long period used in
country pairs [54] was long enough to observe the impact
of screening on mortality. Another limitation is the con-
tamination of mortality data during the screening era with
deaths due to breast cancer diagnosed before screening
start. In 1993, the eight-year survival of deadly (stage III)
breast cancer was about 30% [58]. The study on country
pairs [54] extended over 15 to 19 years after screening
start. Hence most fatal breast cancers diagnosed before
the screening era weighted little in the breast cancer mor-
tality burden after 2000.
Two other studies on long-term breast cancer mortality
trends according to timing of screening introduction were
conducted in Danish regions and in Swedish counties
[36,59]. During the 15 years following screening start, no
change in the difference in mortality trends was noticeable
between the screened and unscreened Danish regions. In
Swedish counties, mortality rates continued to follow the
monotonous downward trends that started in 1972, with-
out sign that screening may have influenced these trends.
Conclusions
Case-control studies are relatively easy and quick to per-
form. However, when cancer mortality is decreasing for
reasons unrelated to screening, this design may not be
able to control the self-selection bias, therefore deaths pre-
vented through other interventions may be attributed to
screening. In this respect, contrary to the suggestion of
Puliti and Zappa [10], a case-control study should not be
considered as the standard method for the evaluation of
breast screening effectiveness.
IBM studies focus on deaths from breast cancer occur-
ring during periods of the same duration before and after
screening introduction. But results from IBM studies seem
to vary according to the design adopted and adjustments
performed during the statistical analysis. Also, results may
be biased if secular trends in mortality, improved treat-
ment and geographical variations in patient management
are not considered.
The method based on incidence trends of advanced
breast cancer corresponds to the primary goal of screening
that consists in preventing advanced cancer. Its main lim-
itation is the paucity of population-based cancer registries
that have collected data on breast cancer characteristics
over long periods of time. Monitoring incidence trends in
women living in areas with screening but not invited to
screening is desirable for verifying that the lack of decreas-
ing trends in advanced cancer is not due to the increasing
prevalence of factors associated with greater risk of
advanced breast cancer.
A comparison of mortality trends between screened and
unscreened areas takes into consideration factors influen-
cing mortality in the areas being compared, but several
methodological requirements need to be met for minimiz-
ing ecological biases, such as a period of observation that
is long enough, availability of data on participation in
screening during the observation period, and availability of
data on major confounding factors like access to
treatment.
Studies based on time trends of advanced disease inci-
dence and cancer-specific mortality, with use of designs
enabling comparisons between periods and geographical
areas, have documented that screening for cervical and
colorectal cancer contributed to decreasing mortality
from these two cancers [44,45,53]. We thus conclude
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that, similarly, an evaluation of the effectiveness of breast
screening should be based on monitoring of advanced
cancer incidence, as well as on mortality trends in areas
with contrasting screening policies where good informa-
tion is available on non-screening factors involved in
mortality, so that ecological biases can be minimized.
Indeed, it remains to be explained why results from these
two types of studies on breast screening effectiveness do
not match the results of Swedish randomized trials.
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